bis-(4-morpholinobutyl) fumarate | 1448896-88-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: bis-(4-morpholinobutyl) fumarate
• 英文别名: bis-(4-morpholin-4-ylbutyl) (2E)-but-2-ene-1,4-dioate；bis(4-morpholin-4-ylbutyl) (E)-but-2-enedioate
• CAS: 1448896-88-5
• 化学式: C₂₀H₃₄N₂O₆
• 分子量: 398.5
• InChiKey: OJUVFVHDISSOCA-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  28
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE
  申请人：XENOPORT, INC.

  公开号：US20130203753A1

  公开（公告）日：2013-08-08

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.

  Morpholino烯丙酸烷基酯，包含该类化合物的药物组合物，以及使用Morpholino烯丙酸烷基酯和药物组合物治疗神经退行性、炎症性和自身免疫性疾病的方法被披露，这些疾病包括多发性硬化症、牛皮癣、肠易激综合征、溃疡性结肠炎、关节炎、慢性阻塞性肺疾病、哮喘、帕金森病、亨廷顿病和肌萎缩侧索硬化症。
• PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS
  申请人：XenoPort, Inc.

  公开号：US20150265707A1

  公开（公告）日：2015-09-24

  Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.

  本发明公开了含有低水平某些杂质的(N,N-二乙氨基甲酰)甲基甲基(2E)丁-2-烯-1,4-二酸酯和/或甲基4-吗啉基丁基(2E)丁-2-烯-1,4-二酸酯的制药组合物和剂型。
• Pharmaceutical compositions of fumaric acid esters
  申请人：ARBOR PHARMACEUTICALS, LLC

  公开号：US11135296B2

  公开（公告）日：2021-10-05

  Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.

  本发明公开了(N,N-二乙基氨基甲酰基)甲基甲基(2E)丁-2-烯-1,4-二酸酯和/或 4-吗啉-4-基丁基(2E)丁-2-烯-1,4-二酸酯的药物组合物和剂型，其中某些杂质的含量较低。
• Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
  申请人：XenoPort, Inc.

  公开号：US20140051705A1

  公开（公告）日：2014-02-20

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
• Pharmaceutical Compositions of Fumaric Acid Esters
  申请人：XenoPort, Inc.

  公开号：US20190117776A1

  公开（公告）日：2019-04-25

  Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.